Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2005-000856-34-IT
EUCTR2005-000856-34-ITActive, not recruitingNot Applicable

A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overwiight patients with essential hypertension

OVARTIS FARMA0 sites480 target enrollmentStarted: December 15, 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
480
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Investigators

Similar Trials

Active, not recruiting
Not Applicable
A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overweight patients with essential hypertensio
EUCTR2005-000856-34-ESovartis Farmacéutica S.A.480
Active, not recruiting
Not Applicable
A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overweight patients with essential hypertensioHypertension
EUCTR2005-000856-34-SEovartis Pharma Services AG480
Active, not recruiting
Not Applicable
A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overweight patients with essential hypertensioHypertension
EUCTR2005-000856-34-FIovartis Pharma Services AG480
Active, not recruiting
Not Applicable
A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ventricular hypertrophy in overweight patients with essential hypertensioHypertension
EUCTR2005-000856-34-DEovartis Pharma Services AG480
Active, not recruiting
Not Applicable
A 36 week, multicenter, randomized, double-blind, placebo- controlled, parallel-group, pilot study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-AMI patients when added to optimized standard therapy - ASPIREHypertension
EUCTR2006-001704-37-NLovartis Pharma Services AG800